Cardiol Therapeutics (QX) Stock Price - CRTPF

2.30
-0.22266 (-8.83%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardiol Therapeutics Inc (QX) CRTPF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.22266 -8.83% 2.30 2.23 2.51 2.51 2.52266 16:30:15
Bid Price Ask Price Spread Spread % News
2.05 2.32 0.27 11.64% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
85 30,147 $ 2.2959 $ 69,214 14,728 1.62 - 7.40
Last Trade Time Type Quantity Stock Price Currency
15:50:21 68 $ 2.29354 USD

Cardiol Therapeutics (QX) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 59.52M 25.88M - - 18.99M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
211.15k $ - 0.00% - -

more financials information »

Cardiol Therapeutics (QX) News

Real-Time news about Cardiol Therapeutics Inc (QX) (OTCMarkets): 0 recent articles

Latest CRTPF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRTPF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.98562.98562.232.7016,001-0.6856-22.96%
1 Month3.123.302.232.9714,366-0.82-26.28%
3 Months2.86243.832.233.2115,026-0.56241-19.65%
6 Months3.4253.831.622.8813,300-1.13-32.85%
1 Year5.40917.401.623.6018,531-3.11-57.48%
3 Years3.706110.001.623.7218,185-1.41-37.94%
5 Years3.706110.001.623.7218,185-1.41-37.94%

Cardiol Therapeutics (QX) Description

Cardiol Therapeutics Inc. is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx, is designed to be one of the safest and most consistent cannabidiol formulations on the market. CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (<10 ppm). The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is also pursuing distribution opportunities in Europe and Latin America. In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.
Your Recent History
USOTC
CRTPF
Cardiol Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200227 21:54:19